Skip to content
hcg-service-hero-1

Insights From Halloran

Elizabeth BodiJan 16, 2025 11:30:00 AM1 min read

Key Update on Guideline for Good Clinical Practice E6(R3)

January 6, 2025: ICH assembly agreed that ICH GCP E6 R3 Principles and Annex 1 could be ...
Start Reading
Nicole GalloJan 13, 2025 11:19:45 AM4 min read

Early FDA Engagement is Essential

Navigating the FDA review process for investigational new drugs (INDs) is the critical ...
Start Reading
Halloran Consulting GroupJan 9, 2025 6:08:23 PM< 1 min read

Groundbreaking Rare Disease Drug Approval (OGSIVEO [nirogacestat]) Propelled by Expert Regulatory Strategy and Program Management

Rare Disease Drug Approval (OGSIVEO [nirogacestat]) SpringWorks Therapeutics, a ...
Start Reading
Rich DanielsJan 6, 2025 9:45:00 AM6 min read

Bridging Continents for Clinical Development

An Interview with Experts on the Australia and United States Global Partnership Advantage
Start Reading
Rich DanielsDec 31, 2024 9:31:00 AM4 min read

Successfully Managing the Transition from Research to Development

The journey from research to development is one of the most critical phases in drug ...
Start Reading
Halloran Consulting GroupDec 17, 2024 7:12:38 PM4 min read

The Butterfly Effect in Clinical Trials: Enhancing Study Quality Through Effective Training

What is The Butterfly Effect?
Start Reading
Eric MossDec 16, 2024 12:52:49 PM2 min read

Three Ways to Accelerate from Trial to Market

Start Reading
Halloran Consulting GroupDec 9, 2024 11:54:24 AM< 1 min read

Best Of Series: Clinical Trial Conduct

ON-DEMAND WEBINAR
Start Reading
Halloran Consulting GroupDec 6, 2024 6:00:00 AM< 1 min read

Turning Your Inspection Fears into Actionable Readiness Steps

As a clinical leader, being inspection ready is critical in the success of an FDA drug or ...
Start Reading
Elizabeth BodiDec 4, 2024 1:00:00 PM< 1 min read

On-Demand: Inspection Readiness A Failure to Plan is a Plan to Fail

ON-DEMAND WEBINAR
Start Reading